Annual Financials for Denali Therapeutics Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | 129.16M | 26.68M | 335.66M | 48.66M | |
Sales Growth |
- | - | -79.34% | 1,158.19% | -85.50% | |
Cost of Goods Sold (COGS) incl. D&A |
3.08M | - | - | - | 5.61M | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
3.08M | 7.42M | 7.99M | 6.17M | 5.61M | |
Depreciation |
3.08M | 7.42M | 7.99M | 6.17M | 5.61M | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | - | - | - | |
Gross Income |
(3.08M) | - | - | - | 43.05M | |
Gross Income Growth |
- | - | - | - | - | |
Gross Profit Margin |
- | - | - | - | 88.47% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
87.06M | 160.22M | 230.37M | 266.77M | 338.8M | |
Research & Development |
71.38M | 135.28M | 191.88M | 212.62M | 265.35M | |
Other SG&A |
15.68M | 24.93M | 38.49M | 54.16M | - | |
SGA Growth |
- | 84.03% | 43.79% | 15.80% | 27.00% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | 8.1M | 1.3M | (100,000) | - | |
EBIT after Unusual Expense |
- | (46.57M) | (212.98M) | 62.82M | - | |
Non Operating Income/Expense |
- | - | - | - | - | |
Non-Operating Interest Income |
1.96M | 10.33M | 15.02M | 9.14M | 4.6M | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | - | - | - | |
Interest Expense Growth |
- | - | - | - | - | |
Gross Interest Expense |
- | - | - | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(88.19M) | (36.24M) | (197.97M) | 71.96M | (291.16M) | |
Pretax Income Growth |
- | 58.90% | -446.26% | 136.35% | -504.61% | |
Pretax Margin |
- | - | - | - | -598.34% | NA |
Income Tax |
- | - | (351,000) | 823,000 | (575,000) | |
Income Tax - Current Domestic |
- | - | - | 823,000 | (576,000) | |
Income Tax - Current Foreign |
- | - | - | - | 1,000 | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(88.19M) | (36.24M) | (197.61M) | 71.14M | (290.58M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(88.19M) | (36.24M) | (197.61M) | 71.14M | (290.58M) | |
Net Income Growth |
- | 58.90% | -445.29% | 136.00% | -508.49% | |
Net Margin Growth |
- | - | - | - | -597.15% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(88.19M) | (36.24M) | (197.61M) | 71.14M | (290.58M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(88.19M) | (36.24M) | (197.61M) | 71.14M | (290.58M) | |
EPS (Basic) |
(5.89) | (0.39) | (2.07) | 0.65 | (2.39) | |
EPS (Basic) Growth |
- | 93.36% | -428.21% | 131.58% | -466.28% | |
Basic Shares Outstanding |
14.96M | 92.62M | 95.61M | 108.97M | 121.52M | |
EPS (Diluted) |
(5.89) | (0.39) | (2.07) | 0.63 | (2.39) | |
EPS (Diluted) Growth |
- | 93.36% | -428.21% | 130.54% | -478.82% | |
Diluted Shares Outstanding |
14.96M | 92.62M | 95.61M | 112.7M | 121.52M | |
EBITDA |
(87.06M) | (31.06M) | (203.69M) | 68.89M | (290.14M) | |
EBITDA Growth |
- | 64.33% | -555.87% | 133.82% | -521.17% | |
EBITDA Margin |
- | - | - | - | -596.25% | NA |